Integrin‐based focal adhesion is one of the major mechanosensory in osteocytes. The aim of this study was to mine the hub genes associated with focal adhesion and investigate their roles in osteoporosis based on the data of single‐cell RNA sequencing and RNA‐sequencing. Two hub genes (FAM129A and RNF24) with the same expression trend and AUC values greater than 0.7 in both GSE56815 and GSE56116 cohorts were uncovered. The nomogram was created to predict the risk of OP based on two hub genes. Subsequently, the competing endogenous RNA network was established based on two hub genes, 14 microRNAs and five long noncoding RNAs. Meanwhile, transcription factors‐hub gene network was established based on two hub genes and 14 TFs. Finally, 73 drugs were predicted, of which there were 13 drugs targeting FAM129A and 66 drugs targeting RNF24. In both mouse and human blood samples, FAM129A expression was decreased in granulocytes and RNF24 expression was increased in monocytes. In the mouse experiment, FAM129A and anti‐RNF24 were found to partially alleviate the progression of osteoporosis. In conclusion, two hub genes related to focal adhesion were identified by combined scRNA‐seq and RNA‐seq analyses, which might supply a new insight for the treatment and evaluation of OP.
Osteoporosis is characterized by dysregulated osteoclast activity, leading to excessive bone resorption and structural damage. In this study, we developed pH‐responsive ZIF‐90 nanoparticles loaded with puerarin (PU) (ZIF‐90@PU) for microenvironment‐responsive osteoporosis therapy through epigenetic modulation. Following self‐assembly, the nanoparticles underwent dynamic light scattering (DLS), field emission scanning electron microscopy (FE‐SEM), powder X‐ray diffraction (PXRD), Fourier‐transform infrared spectroscopy (FTIR), and X‐ray photoelectron spectroscopy (XPS); these analyses verified efficient puerarin encapsulation and pH‐triggered release. In cell‐based experiments, ZIF‐90@PU suppressed the differentiation of bone marrow‐derived macrophages (BMMs) into osteoclasts while promoting osteogenic differentiation of bone marrow‐derived mesenchymal stem cells (BMSCs). Administration of ZIF‐90@PU to ovariectomized (OVX) mice produced significant gains in bone mineral density, trabecular architecture, and bone strength without detectable toxicity. Mechanistically, ZIF‐90@PU treatment was associated with increased H3K18 lactylation and reduced NFATc1 signaling, accompanied by suppression of osteoclast activation. This study introduces ZIF‐90@PU as a novel epigenetic‐modulating nanomedicine for osteoporosis treatment.
This study examined the feasibility and effectiveness of utilizing the single-person reset fixed system (RFS) for treating pediatric supracondylar humeral fractures (SHFs) to enhance surgical efficiency and reduce manpower requirements. A retrospective analysis of 10 pediatric SHF cases treated with the Single-Person RF was conducted from 2022 to 2023. The primary variables of interest were surgical time, fluoroscopy frequency, postoperative outcomes, and complication rates. All patients achieved successful single-stage surgical reduction and fixation without additional surgeries. The surgical time was 55 min, with an average fluoroscopy frequency of 11.8 times. Postoperatively, Baumann's Angle ranged from 64 to 81 degrees, indicating restoration of normal joint mobility as Range of Motion (ROM) exceeded 90%. The meta-analysis highlighted the significant advantage of the Single-Person RFS in improving the excellent treatment rate with low heterogeneity. The single-person RFS demonstrates remarkable effectiveness in pediatric SHF treatment, evident through reduced surgical times, decreased fluoroscopy frequency, minimal complications, and positive functional recovery for patients. The findings emphasize the superiority of the single-person RFS in enhancing treatment outcomes, suggesting future optimization and potential broader applications in fracture management.